Eurofins Scientific SE (ENXTPA:ERF) commences share repurchases on April 25, 2025, under the program mandated by the shareholders in the Annual General Meeting held on April 24, 2025. As per the mandate, the company is authorized to repurchase up to 10% of its issued shares. The minimum price to be paid for share repurchase should be its nominal value of one share and the maximum price to be paid for repurchase should not exceed 110% of the purchase price of the share on the Euronext Paris market or any other regulated market on which the securities of the Company are traded, depending on the market on which the transactions are carried out and for off-market transactions, the maximum price to be paid for repurchase will be 110% of the reference price on the Euronext Paris market.
The reference price will be deemed to be the average of the closing price during the thirty (30) consecutive days during which this market is open for trading preceding the three (3) trading days prior to the purchase date. The purpose of the program is to to cancel shares, to enable the Company to allocate the shares acquired to the holders of securities giving access to the Company's share capital on the exercise of the rights attached to such securities, to enable the Company to allocate the shares acquired to employees and authorized corporate officers, directors or independent consultants of the Company or its direct and indirect subsidiaries and/or associated companies, to stimulate the share price under a liquidity contract with an independent investment services provider, to retain the acquired shares and subsequently tender them in exchange or as consideration for any future external growth transactions and to enable the Company to pay out dividends (or other distributions) in kind, among others, in part or in full with shares repurchased. The authorization will be valid for 5 years.
